Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Fund Details
Upturn AI Summary
ProShares Ultra Nasdaq Biotechnology(BIB)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for BIB
10/09/2026: BIB (2-star) is currently NOT-A-BUY. Pass it for now.
ProShares Ultra Nasdaq Biotechnology (BIB) is a leveraged ETF designed to provide 2x the daily performance of the Nasdaq Biotechnology Index using derivative strategies. Its main strengths lie in its liquidity and utility for short-term tactical traders seeking amplified exposure to biotech market moves. However, it is not intended for long-term holding, as daily rebalancing leads to significant volatility decay and tracking error. The primary risks involve high sector concentration, leverage-induced losses, and sensitivity to regulatory or clinical news. It is best suited for experienced investors who can actively monitor their positions and understand the mechanics of daily leveraged reset products.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
ETF holdings, costs, diversification, valuation, risks, and market conditions provide supporting context about the fund.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Weak fit | Leveraged ETFs are designed for daily tactical trading rather than long-term growth investment. |
| Momentum investor | Strong fit while signal remains positive | The 2x leverage enhances momentum plays during strong, short-term trends in the biotechnology sector. |
| Value investor | Weak fit | The daily reset mechanism is counterproductive for value investors seeking to capture fundamental long-term growth. |
| Dividend/Income investor | Weak fit | This fund provides no income and is unsuitable for capital preservation strategies. |
| Low-risk investor | Weak fit | The inherent volatility and tracking decay make this fund unsuitable for risk-averse portfolios. |
Investor Profile
Ideal Investor Profile
The ideal investor is an experienced, active trader with a high risk tolerance and a clear, short-term tactical hypothesis.
Suitability
BIB is strictly for short-term tactical trading and is unsuitable for long-term passive index followers.
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Volatility | High | The 2x leverage multiplier significantly amplifies daily price swings compared to the underlying index. |
| Market risk | High | The fund is fully exposed to the directional risks of the biotechnology sector, which is prone to sudden, news-driven corrections. |
| Concentration | High | The fund is concentrated in a single sector, leaving it vulnerable to industry-specific shocks. |
| Tracking/expense | High | Mathematical compounding and high expense ratios lead to significant tracking error over periods longer than one day. |
| Liquidity | Medium | While generally liquid, volatility in underlying holdings can impact the ease of executing large trades. |
| Business/sector quality | Medium | Biotechnology relies heavily on innovation and regulatory approval, which are binary and unpredictable. |
Risk Analysis
Volatility
BIB exhibits high historical volatility due to its 2x daily leverage target.
Market Risk
The fund is subject to concentrated sector risk, meaning its performance is tied strictly to the Nasdaq Biotechnology Index.
What the ETF Owns
| Exposure Type | Exposure | Weight (%) | Retail Investor Read |
|---|---|---|---|
| Derivatives | Nasdaq Biotechnology Index (seeks 2x daily return) | 95 | The fund primarily utilizes swaps and futures to provide double the daily performance of the benchmark biotechnology index. |
| Cash/collateral | Cash and Cash Equivalents | 5 | Cash holdings are maintained to serve as collateral for derivative positions and to manage daily liquidity requirements. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type ETF | Historic Profit 73.91% | Avg. Invested days 65 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | ETF Returns Performance  5.0 |
| Profits based on simulation | Last Close 10/09/2026 |
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.